What is UroGen Pharma's stock-based comp?

UroGen Pharma (URGN) reported stock-based comp of $4.63M in Q1 2026.

How has UroGen Pharma's stock-based comp changed year-over-year?

UroGen Pharma's stock-based comp increased by 50.8% year-over-year, from $3.07M to $4.63M.

What is the long-term trend for UroGen Pharma's stock-based comp?

Over 4 years (2021 to 2025), UroGen Pharma's stock-based comp has grown at a -15.2% compound annual growth rate (CAGR), from $23.11M to $11.96M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

UroGen Pharma URGN Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

PfizerPFE

$272M+60.0%

Johnson & JohnsonJNJ

$300M+4.2%

Merck & Co.MRK

$185M-5.1%

ImmunityBio, Inc.IBRX

$8.17M-14.3%

Tyra Biosciences, Inc.TYRA

$7.85M+22.2%

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's stock-based comp?: UroGen Pharma (URGN) reported stock-based comp of $4.63M in Q1 2026.
How has UroGen Pharma's stock-based comp changed year-over-year?: UroGen Pharma's stock-based comp increased by 50.8% year-over-year, from $3.07M to $4.63M.
What is the long-term trend for UroGen Pharma's stock-based comp?: Over 4 years (2021 to 2025), UroGen Pharma's stock-based comp has grown at a -15.2% compound annual growth rate (CAGR), from $23.11M to $11.96M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.